Home/ Stocks/ SAVA

Cassava Sciences, Inc.

SAVA XNAS

$2.13 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$102.90M

About Cassava Sciences, Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 30 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-10,807,000	$-0.22
Q2 2025	$0	$-44,224,000	$-0.92
Q1 2025	$0	$-23,403,000	$-0.48
Q3 2024	$0	$-27,943,000	$-0.58

Ticker Daily Articles on SAVA

How to Build a Penny Stock Scanner (Step-by-Step)

Marcus Rivera · 5h ago · News

Get SAVA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cassava Sciences, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.